Roflumilast for psoriasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Aug 2025: Trial started, NCT07233291
  2. 18 Nov 2025: Trial registered, NCT07233291

The trials

NCT07233291: A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults

State
Under way
Phase
Phase 2
People
36 planned
Started
20 Aug 2025
Primary completion
28 Feb 2026
Arms
Oral Roflumilast for Adults with Moderate-to-Severe Psoriasis
Results
None posted
  1. 20 Aug 2025: Trial started
  2. 18 Nov 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as ARQ-154, Daliresp, Daxas, Roflumilast Foam, Roflumilast Foam 0.3%, Zoryve.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.